Search

Alirocumab

Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of … It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval.

Doxazosin

[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285] … Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension.

Mavacamten

It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. … Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM).

Medroxyprogesterone acetate

manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma. … [A14848] MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy,

(S)-DES-ME-AMPA

Benzalkonium

Benzalkonium is more commonly contained in consumer products in its salt form, benzalkonium chloride [FDA Label]. … When used as an ingredient in antiseptic and disinfectant products however, it is an active antimicrobial agent [L1806].

Pinaverium

Pinaverium bromide is the common ingredient in formulations, mostly as oral tablets. … Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada.

Neomycin

[L11979] It is also used in combination with [polymyxin B] sulfates and [hydrocortisone] in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections … [L10532] Neomycin is also used in combination with [polymyxin B] sulfates and [dexamethasone] in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye.

Lanreotide

It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007. … Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome

Erenumab

CGRP receptor, which is believed to play a critical role in migraine [L2823]. … The antibody is produced utlilizing recombinant DNA technology in Chinese hamster ovary cells [FDA Label].